CLSI Hosts CARB-X Information and Networking Session
Entrepreneurship
CLSI FAST Company Female Execs Defy Industry Norm | Read More
CSweetener: Mentoring for Women Healthcare Leaders | Read More
Inflammatix (FAST Fall 2017) is named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests | Read More
Fatma Kaplan, CEO of Pheronym(FAST Fall 2017) talks about encountering high risk to get to the goal in sight | Read More
LogicInk (FAST Spring 2017) highlighted in the Proceedings of the National Academy of Sciences (PNAS): “Science and Culture: Wearable tech meets tattoo art in a bid to revolutionize both” | Read More
Eidos Therapeutics (FAST Spring 2016) announced completion of a $64.0 million Series B financing to advance Eidos’ small molecule product candidate, AG10 into Phase 2 clinical trials for the treatment of transthyretin (TTR) amyloidosis (ATTR) | Read More
Sandstone Diagnostics (FAST Fall 2013) deployed in a new NIH-funded research study to further evaluate the association between men’s semen parameters and fertility among couples trying to conceive | Read More
CLSA Fellows member twoXAR raised $10 million in a Series A financing led by SoftBank Ventures to build the company’s drug pipeline | Read More
ShangPharma Innovation expanded its incubator facility to provide science-driven entrepreneurs with affordable access to resources such as laboratory infrastructure and conferencing space | Read More
The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.
Read Op-Ed by Kevin Outterson, Executive Director of CARB-X, about innovative ways to pay for new antibiotics in STAT news. | Read More
CARB-X awards up to $2 million to HelixBind for the development of the company’s RaPID/BSI diagnostic test for invasive bloodstream infections | Read More
CARB-X awards up to $7.6 million to Shionogito develop an antibiotic to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE) | Read More
CARB-X awards up to $1.7 million to Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood | Read More
Powered by CARB-X company, Macrolide Therapeutics announced completion of a $20 million financing led by Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Ventures and SR One and appointment of a new CEO | Read More
Powered by CARB-X company, T2 Biosystems, announced positive results from four studies of its T2Dx blood diagnostics system designed to detect pathogens that cause sepsis | Read More
Other AMR News
Genentech researchers have identified an antibody that spotlights a new target for antibiotic resistant bacteria, potentially paving the way for a new class of antibiotics | Read More
Researchers at Brown University may have discovered a new class of antibiotics chemically related to vitamin A that shows early promise by killing MRSA in mice | Read More
Arsanis, a clinical-stage biopharmaceutical company developing monoclonal antibodies for targeted immunotherapy of serious infections, announced an out-license agreement with BB100 for their preclinical stage E.coli monoclonal antibodies | Read More
Deinove, a France-based biotechnology company expanded its innovative antibiotic portfolio by signing a license option agreement with RedX Pharma for its first-in-class NBTI anti-infective program targeting resistant Gram-negative bacteria | Read More
Using high resolution microscopy, scientists have developed a new perspective on the bacterial cell wall Read More. Another group of scientists have discovered a structural weak spot in the cell wall, which may be a targetable spot for new antibacterial drugs Read More.
CARB-X is one of the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative products from ‘hit-to-lead’ phase through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI). http://www.carb-x.org/.
Upcoming Events
4/16
Duke-Margolis - Evaluating Inclusion and Exclusion Criteria in Clinical Trials, Washington D.C.
CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.
California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.
CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.
California Life Sciences Institute 685 Gateway Blvd., Suite 100 South San Francisco California 94080
You received this email because you are subscribed to Events from California Life Sciences .
Update your email preferences to choose the types of emails you receive.
